WATCH- Taysha Gene Therapies added to ICE Biotechnology Index 07:04 TSHA Taysha Gene Therapies announced that it has been added to the ICE Biotechnology Index in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021. "Taysha's inclusion in this key biotechnology index provides important validation of our platform and value proposition as a company," said RA Session II, President, Founder and CEO of Taysha. "We remain focused on executing our near-term clinical and regulatory milestones, which we believe will continue to increase our visibility within the investment community." HEYDUDE? Sounds stupid- Crocs to acquire HEYDUDE for $2.5B 07:02 CROX Crocs announced that it has entered into a definitive agreement to acquire HEYDUDE, a privately-owned casual footwear brand, for $2.5B. The purchase price of $2.5B, subject to customary closing adjustments, will be funded by $2.05B in cash and $450M in Crocs shares issued to Rosano based on the average of the daily volume-weighted average price of our stock for the 20 days immediately prior to the signing date. "We expect to enter into a $2.0 billion Term Loan B Facility and borrow $50 million under the company's existing Senior Revolving Credit Facility to fund the cash consideration." The transaction is expected to close in the first quarter of 2022, subject to customary closing conditions and regulatory approval. Upon completion of the transaction, HEYDUDE will operate as a standalone division. Alessandro Rosano, founder of HEYDUDE, will continue to lead innovative product development as Strategic Advisor and Creative Director. As part of this transaction, Rick Blackshaw was hired to join HEYDUDE as Executive Vice President and Brand President. Blackshaw brings over 25 years of footwear experience and most recently served as the CEO at CCM Hockey and previously held positions as the President of Sperry, President of Keds, and Vice President / General Manager of the Chuck Taylor division of Converse. Blackshaw will be a member of the Crocs Executive Leadership Team and report to CEO Andrew Rees.
-- So traveling on a plane is a big problem. -- Studies have shown some shocking numbers of infection. You are very likely to get Omicrom on a plane. This has serious ramifications to our economy and state of mind.- Very distressing article in Times today about college suicide and depression. Folks we have a problem-- these kids. Because of Covid they are not ready for the pressures of college and now to be told virtual again... VAN ACC I sold>
They had several airline experts on saying it's the safest air in the world. CEO of DAL even said that. Hepa filters etc. Of course what else is he gonna say ya know. I think in time everyone is gonna get Omni. I know 4 people right now. It's like a cold. They're all vaxed though. One dude its his second time. The first was the old school covid. Re Mrs Stoney and Louis Vuittan.... probably a good idea. It has always amazed me over the years how well those designer type stocks do. They always go up when the market drops it seems. I don't think you should have sold ACC. Those rooms won't go empty Stoney. I think you might be over reacting. It's a good inflation hedge stock. If it ever pulls back get back in. It'll probably see $53 again. I'm in around 51 and change. No comment on this January put buying by the whales?
--No comment on this January put buying by the whales? I am on record saying Jan is a big problem. My view is Apple is ready to be sold. A whole lot of people didn't want the tax hit this year myself included. It's up too much. But once it becomes a last person out situation.. somewhere between I phone 13 let down and the car there is a decent correction that will take the averages down. I'm sort of in the camp that the other stuff has already been wrecked as you know so even though the averages come down the average stock will be flat. I am not looking for a good 2022. Regarding ACC that 1 California college going virtual is now six or seven> Really deep article in the Times I encourage everyone to read about the kids now. We have a situation- this is bigger than Covid. I'm not here to make money off every idea as I showed with the Trump stock Twice_! But mental health... Is that Teladoc? Would kids use that....
They had several airline experts on saying it's the safest air in the world. This is a lie Van. You know I am a conspiracy guy obviously but there is a British report that our Gov squashed and it was SCARY! It basically said take a flight catch Omicrom. It's particles are so much finer they don't sink to the floor of the plane they stay aerosol , in the air<----
All right here is the news I knew was coming-- FDA says Lilly, Regeneron monoclonal antibodies ineffective against omicron 12:29 REGN, GSK, VIR, LLY Data show that it is unlikely that monoclonal antibodies bamlanivimab and etesevimab, made by Eli Lilly (LLY), administered together or Regeneron's (REGN) REGEN-COV will retain activity against the omicron variant, the Food and Drug Administration said in a statement. Based on similar cell culture data currently available, GlaxoSmithKline (GSK) and Vir Biotechnology's (VIR) sotrovimab appears to retain activity against the omicron variant, the agency added. Based on this information, the Assistant Secretary for Preparedness and Response will pause any further allocations of bamlanivimab and etesevimab together, etesevimab alone, and REGEN-COV pending updated data from the Centers for Disease Control and Prevention.
Luminar boosts stock buyback plan to over $300M 12:20 LAZR Luminar Technologies announced the successful execution of its previously announced transaction, with the intent to purchase shares and accelerate growth. The deal was oversubscribed based on positive institutional investor support, and upsized to a total of $625M in gross proceeds. Luminar expects to use over $300M of the proceeds for LAZR share purchases, while the remaining capital will bolster Luminar's balance sheet. Luminar intends to use the net proceeds to accelerate business growth including: series production capacity expansion, new commercial wins, technology roadmap advancement, international expansion, and accelerating software development. Luminar remains on track to enter the series production phase by the end of 2022.
Planet Labs PBC call volume above normal and directionally bullish 12:25 PL Bullish option flow detected in Planet Labs PBC with 4,222 calls trading, 1.1x expected, and implied vol increasing over 3 points to 130.85%. Apr-22 12.5 calls and Jan-22 7.5 calls are the most active options, with total volume in those strikes near 2,000 contracts. The Put/Call Ratio is 0.06. Earnings are expected on March 14th. up 11%!
Pullback in Crocs shares 'a compelling' buying opportunity, says Baird 11:22 CROX After speaking with Crocs following the announced acquisition of casual footwear brand HEYDUDE for $2.5B, Baird analyst Jonathan Komp says there are no changes in his positive view of the company, now including the planned acquisition. The analyst believes the pullback in shares is "significantly overdone" and sees it as a "compelling" buying opportunity. Komp has an Outperform rating and a price target of $250 on the shares.
Crocs shares 'mispriced' following accretive deal, says Piper Sandler 11:16 CROX Piper Sandler analyst Erinn Murphy remains a buyer of Crocs shares following news of the company acquiring Hey Dude. The analyst says she's been monitoring Hey Dude and says it is one of fastest rising brands she's seen to date in Piper's semi-annual survey of teens. Hey Dude is roughly the size of Crocs in the Americas back in 2018, ending 2021 at $570M, and its profitability is strong, Murphy tells investors in a research note. With Crocs shares down 15% today, the analyst sees an "opportune time to be accumulating the stock," particularly following the "accretive deal" that could add over $1 per share in earnings in fiscal 2022. The shares are "mispriced this morning" as investors are unfamiliar with the Hey Dude brand, writes Murphy. She keeps an Overweight rating on Crocs with a $215 price target. Show Related Items >>